MCC
IBRX icon

Money Concepts Capital’s ImmunityBio IBRX Stock Holding History

Money Concepts Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,889
Closed -$56.2K – 407
2023
Q1 		$56.2K Buy
30,889
+187
+0.6% +$581 ﹤0.01% 456
2022
Q4 		$156K Buy
30,702
+580
+2% +$3.19K 0.01% 791
2022
Q3 		$150K Buy
+30,122
New +$137K 0.01% 480

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Money Concepts Capital's IBRX Position: Q2 2023 in Review

Money Concepts Capital sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 30,889 shares — an estimated $56.2K sold.

Money Concepts Capital first reported a position in IBRX in Q3 2022 and held it in 3 quarters. The position peaked at $156K in Q4 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Money Concepts Capital reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Money Concepts Capital sold 30,889 ImmunityBio shares in Q2 2023, an estimated $56.2K.
  • Money Concepts Capital first reported a position in ImmunityBio in Q3 2022 and held it in 3 quarters.
  • Money Concepts Capital's ImmunityBio position peaked at $156K in Q4 2022.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Money Concepts Capital's 13F filing for Q2 2023, filed 1 Aug 2023.